Immuno-Oncology News

September 23, 2020September 23, 2020

EU Approval Recommended for Opdivo-Yervoy-Chemo Combo for Advanced NSCLC

A European Medicines Agency (EMA) committee has recommended that a combination therapy of Opdivo (nivolumab) and Yervoy (ipilimumab) plus two cycles of platinum-based chemotherapy be approved in the European Union (EU) as first-line treatment for advanced non-small ... Read more

September 21, 2020September 21, 2020

FDA Acts to Speed Toripalimab as Potential Nasopharyngeal Cancer Treatment

Immuno-Oncology News

The U.S. Food and Drug Administration (FDA) has designated toripalimab (JS001) a breakthrough therapy as a potential treatment of nasopharyngeal carcinoma (NPC), one of the most common cancers in China and one lacking treatment ... Read more

September 18, 2020September 19, 2020

EMA to Review Opdivo-Yervoy Combo for Untreated, Inoperable Mesothelioma

Immuno-Oncology News

The European Medicines Agency has agreed to review Bristol Myers Squibb’s application requesting approval for the dual immunotherapy regimen Opdivo (nivolumab) and Yervoy (ipilimumab) for untreated, inoperable malignant pleural mesothelioma (MPM). This decision ... Read more

September 14, 2020September 14, 2020

Post-surgery Opdivo Shows Benefits for Esophageal, GEJ Cancer Patients in Ongoing Trial

Immuno-Oncology News

Opdivo (nivolumab) significantly prolongs the time patients with resected esophageal or gastroesophageal junction (GEJ) cancer live without signs of disease after receiving chemoradiation therapy followed by cancer removal surgery, interim ... Read more

September 9, 2020September 9, 2020

Strong Response for Tessa’s CD30 CAR-T Cell Therapy in Hodgkin’s Lymphoma Trial

Immuno-Oncology News

Tessa Therapeutics’ investigational CD30 CAR-T cell therapy is safe and leads to a high rate of strong and sustained responses in people with relapsed or treatment-resistant Hodgkin’s lymphoma, according to ... Read more

September 4, 2020September 4, 2020

FDA Rejects Keytruda-Lenvima Combo as First-line Treatment for Liver Cancer

Immuno-Oncology News

The U.S. Food and Drug Administration (FDA) has issued a complete response letter stating that it will not approve the combination of Keytruda (pembrolizumab) plus Lenvima (lenvatinib) as a first-line treatment for people ... Read more

September 2, 2020September 2, 2020

Imfinzi Approved in EU for Extensive-stage Small Cell Lung Cancer

Immuno-Oncology News

The European Commission has approved a combination of Imfinzi (durvalumab) plus standard chemotherapy as a first-line treatment for people with extensive-stage small cell lung cancer (SCLC). Findings from the CASPIAN ... Read more

August 31, 2020August 31, 2020

Imfinzi as Once Monthly NSCLC, Bladder Cancer Treatment Under FDA Review

Immuno-Oncology News

The U.S. Food and Drug Administration (FDA) has accepted and given priority review to AstraZeneca‘s application requesting a new dosing regimen for Imfinzi (durvalumab) to treat certain non-small cell lung cancer (NSCLC) and bladder ... Read more

August 26, 2020August 26, 2020

Novocure, MSD Team Up to Test TTFields-Keytruda Combo in Lung Cancer

Immuno-Oncology News

An upcoming Phase 2 clinical trial is set to evaluate Novocure‘s Tumor Treating Fields, known as TTFields, in combination with Keytruda (pembrolizumab) for the treatment of non-small cell lung cancer ... Read more

August 17, 2020August 17, 2020

Health Canada Approves Opdivo-Yervoy-Chemo Combo for Advanced NSCLC

Immuno-Oncology News

Health Canada has approved a combination therapy of Opdivo (nivolumab) and Yervoy (ipilimumab) plus two cycles of platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer (NSCLC). The approval ... Read more

August 12, 2020August 12, 2020

Opdivo-Yervoy Combo Prolongs Survival of Patients With Inoperable Mesothelioma, Phase 3 Trial Shows

Immuno-Oncology News

A dual immunotherapy regimen of Opdivo (nivolumab) and Yervoy (ipilimumab) can prolong the survival of patients with untreated, inoperable malignant pleural mesothelioma (MPM), according to data from a Phase 3 clinical ... Read more

August 7, 2020August 7, 2020

FDA Clears FT819 CAR T-cell Therapy for Clinical Testing in Lymphoma, Leukemia

Immuno-Oncology News

Fate Therapeutics will soon initiate a Phase 1 trial investigating its CAR T-cell therapy, FT819, across several B-cell cancers, including chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and non-Hodgkin’s ... Read more

August 3, 2020August 3, 2020

FDA Approves Tecentriq Combo for Certain Advanced Melanomas

Immuno-Oncology News

The U.S. Food and Drug Administration (FDA) has approved the immunotherapy Tecentriq (atezolizumab), in combination with Cotellic (cobimetinib) and Zelboraf (vemurafenib), for the treatment of BRAF V600 mutation-positive advanced melanoma. The ... Read more

July 31, 2020August 3, 2020

Yale Researcher Wins NIH Merit Award, Supporting Immunotherapy Work

Immuno-Oncology News

The National Institutes of Health (NIH) has given an R37 Merit Award to support the work of Kurt Schalper, MD, PhD, in the field of immunotherapy for the next seven ... Read more

July 28, 2020July 28, 2020

CAR T-cell Therapy Tecartus Granted FDA Approval for Mantle Cell Lymphoma

Immuno-Oncology News

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Kite Pharma’s CAR T-cell therapy Tecartus (brexucabtagene autoleucel) for adults with relapsed or refractory mantle cell lymphoma (MCL). The decision ... Read more